BT563 significantly decreases sIL-2R plasma levels despite acute allograft rejection

Transplant Proc. 1996 Dec;28(6):3103-5.

Authors

A R Mueller¹, K P Platz, T Steinmüller, N Nüssler, U Neumann, H Gerlach, C Stoll, W O Bechstein, P Neuhaus

Affiliation

¹ Department of Surgery, Virchow Clinic, Humboldt University of Berlin, Germany.

PMID: 8962203

No abstract available

Publication types

Comparative Study

MeSH terms

Actuarial Analysis
Analysis of Variance
Antibodies, Monoclonal / therapeutic use*
Antilymphocyte Serum / therapeutic use
Biomarkers / blood*
Cell Adhesion Molecules / blood*
Cyclosporine / therapeutic use
Drug Monitoring
Follow-Up Studies
Graft Rejection / blood
Graft Rejection / immunology*
Graft Rejection / mortality
Graft Survival / immunology*
Humans
Immunosuppression Therapy
Immunosuppressive Agents / therapeutic use*
Intercellular Adhesion Molecule-1 / blood
Liver Transplantation / immunology*
Liver Transplantation / mortality
Receptors, Interleukin-2 / analysis*
Reoperation
Retrospective Studies
Time Factors
Transplantation, Homologous
Vascular Cell Adhesion Molecule-1 / blood

Substances

Antibodies, Monoclonal
Antilymphocyte Serum
Biomarkers
Cell Adhesion Molecules
Immunosuppressive Agents
Receptors, Interleukin-2
Vascular Cell Adhesion Molecule-1
Intercellular Adhesion Molecule-1
Cyclosporine
inolimomab